Pharmacoeconomics and formulary decision making

被引:15
作者
Sanchez, LA [1 ]
机构
[1] EMRON INC,HLTH ECON,BOSTON,MA
关键词
D O I
10.2165/00019053-199600091-00005
中图分类号
F [经济];
学科分类号
02 ;
摘要
Pharmacoeconomic assessment of formulary actions has become increasingly common in local, national, and international formulary decision making. Tactics for managing medication use include formulary management and drug policies. Pharmacoeconomic data can provide support for these formulary decisions. For example, pharmacoeconomic data can support the inclusion or exclusion of a drug on or from the formulary and support practice guidelines that promote the most cost-effective or appropriate utilisation of pharmaceutical products. Various strategies can be used to incorporate pharmacoeconomics into formulary decision making. These include using published pharmacoeconomic studies and economic modelling techniques, and conducting local pharmacoeconomic research. Criteria for evaluating the pharmacoeconomic literature, suggestions for employing economic models, and suggested guidelines for conducting pharmacoeconomic projects are discussed. Although most formularies are viewed as cost-containment tools, formularies should not be a list of the 'cheapest' alternatives. Today's formulary should contain agents that optimise therapeutic outcomes while controlling costs. Pharmacoeconomic assessments of formulary decisions help to ensure that the agents promoted by our formularies yield the highest outcome per dollar spent. A discussion of the process for formulary action in a US hospital, the influence of pharmacoeconomics on US formularies, and strategies for incorporating pharmacoeconomics into formulary decision making are presented in this paper.
引用
收藏
页码:16 / 25
页数:10
相关论文
共 29 条
[1]  
Barr J T, 1994, Top Hosp Pharm Manage, V13, P60
[2]   FORMULARY EVALUATION OF 2ND-GENERATION CEPHAMYCIN DERIVATIVES USING DECISION-ANALYSIS [J].
BARRIERE, SL .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1991, 48 (10) :2146-2150
[3]  
BOOTMAN JL, 1991, PRINCIPLES PHARMACOE
[4]   DECISION-ANALYSIS APPLIED TO SELECTION OF HISTAMINE H-2-RECEPTOR ANTAGONISTS FOR THE FORMULARY [J].
CALVO, MV ;
FRUNS, I ;
DOMINGUEZGIL, A .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1990, 47 (09) :2002-2006
[5]  
CLEMENS K, 1995, PHARMACOECONOMICS, V8, P469
[6]   ECONOMIC-ASPECTS OF CLINICAL DECISION-MAKING - APPLICATIONS OF CLINICAL DECISION-ANALYSIS [J].
CRANE, VS .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1988, 45 (03) :548-553
[7]  
Detsky A S, 1993, Pharmacoeconomics, V3, P354, DOI 10.2165/00019053-199303050-00003
[8]   USE AND MISUSE OF THE TERM COST-EFFECTIVE IN MEDICINE [J].
DOUBILET, P ;
WEINSTEIN, MC ;
MCNEIL, BJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (04) :253-256
[9]  
Drummond M, 1993, Int J Technol Assess Health Care, V9, P26
[10]  
DRUMMOND MF, 1987, METHODS EC EVALUATIO, P5